Ulland Investment Advisors LLC Sells 920 Shares of Boston Scientific Co. (NYSE:BSX)

Ulland Investment Advisors LLC lessened its stake in shares of Boston Scientific Co. (NYSE:BSX) by 5.9% during the 1st quarter, Holdings Channel reports. The firm owned 14,599 shares of the medical equipment provider’s stock after selling 920 shares during the quarter. Boston Scientific comprises approximately 1.2% of Ulland Investment Advisors LLC’s investment portfolio, making the stock its 22nd largest position. Ulland Investment Advisors LLC’s holdings in Boston Scientific were worth $1,473,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of BSX. USA Financial Formulas boosted its holdings in shares of Boston Scientific by 23.4% in the 1st quarter. USA Financial Formulas now owns 17,937 shares of the medical equipment provider’s stock valued at $1,809,000 after acquiring an additional 3,401 shares during the last quarter. Redhawk Wealth Advisors Inc. raised its position in Boston Scientific by 10.0% during the first quarter. Redhawk Wealth Advisors Inc. now owns 4,239 shares of the medical equipment provider’s stock worth $428,000 after acquiring an additional 385 shares during the period. Assenagon Asset Management S.A. raised its position in Boston Scientific by 161.9% during the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock worth $250,757,000 after acquiring an additional 1,536,663 shares during the period. Integrated Advisors Network LLC raised its position in Boston Scientific by 4.5% during the first quarter. Integrated Advisors Network LLC now owns 6,836 shares of the medical equipment provider’s stock worth $690,000 after acquiring an additional 296 shares during the period. Finally, Trueblood Wealth Management LLC raised its position in shares of Boston Scientific by 38.1% in the first quarter. Trueblood Wealth Management LLC now owns 4,321 shares of the medical equipment provider’s stock valued at $436,000 after buying an additional 1,191 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.0%

Shares of NYSE:BSX opened at $99.38 on Thursday. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company has a 50 day moving average of $100.70 and a 200-day moving average of $98.55. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock has a market cap of $147.03 billion, a price-to-earnings ratio of 79.50, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the firm earned $0.56 EPS. Boston Scientific’s quarterly revenue was up 20.9% compared to the same quarter last year. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares of the company’s stock, valued at approximately $3,441,592.37. The trade was a 11.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of Boston Scientific stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the transaction, the executive vice president now directly owns 22,235 shares in the company, valued at approximately $2,269,304.10. The trade was a 43.78% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Evercore ISI increased their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a research report on Thursday, April 24th. Truist Financial lifted their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the company a “buy” rating in a research report on Thursday, April 24th. Erste Group Bank raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, May 8th. Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. Finally, Citigroup restated a “buy” rating and set a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Twenty-one research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $116.00.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.